NO20055417L - Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor - Google Patents

Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor

Info

Publication number
NO20055417L
NO20055417L NO20055417A NO20055417A NO20055417L NO 20055417 L NO20055417 L NO 20055417L NO 20055417 A NO20055417 A NO 20055417A NO 20055417 A NO20055417 A NO 20055417A NO 20055417 L NO20055417 L NO 20055417L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
composition containing
histone deacetylase
deacetylase inhibitor
containing histone
Prior art date
Application number
NO20055417A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055417D0 (no
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20055417D0 publication Critical patent/NO20055417D0/no
Publication of NO20055417L publication Critical patent/NO20055417L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055417A 2003-05-26 2005-11-16 Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor NO20055417L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (2)

Publication Number Publication Date
NO20055417D0 NO20055417D0 (no) 2005-11-16
NO20055417L true NO20055417L (no) 2005-12-19

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055417A NO20055417L (no) 2003-05-26 2005-11-16 Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (https=)
EP (1) EP1626719A1 (https=)
JP (1) JP2006526031A (https=)
KR (1) KR100938712B1 (https=)
CN (2) CN101322707A (https=)
AR (1) AR045318A1 (https=)
AU (1) AU2004241873C1 (https=)
BR (1) BRPI0410959A (https=)
CA (4) CA2634766A1 (https=)
CL (1) CL2004001278A1 (https=)
CO (1) CO5660262A2 (https=)
CR (1) CR8163A (https=)
CU (1) CU23490B7 (https=)
EC (1) ECSP056253A (https=)
IL (1) IL171941A0 (https=)
ME (1) MEP32308A (https=)
MX (1) MXPA05012345A (https=)
NO (1) NO20055417L (https=)
NZ (1) NZ543591A (https=)
PE (1) PE20050206A1 (https=)
RS (1) RS20050884A (https=)
RU (1) RU2322971C2 (https=)
TW (1) TW200505424A (https=)
UA (1) UA81499C2 (https=)
UY (1) UY28330A1 (https=)
WO (1) WO2004103369A1 (https=)
ZA (1) ZA200509515B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339631B1 (no) * 2004-10-08 2017-01-16 Indena Spa Semisynteseprosess for fremstillingen av 10-deacetyl-N-debenzoyl-paklitaxel.

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20080234265A1 (en) * 2005-03-11 2008-09-25 The Regents Of The University Of Colorado Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
AU2007214458C1 (en) 2006-02-14 2012-12-06 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
RU2446796C2 (ru) * 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PE20141062A1 (es) * 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
ES2663222T3 (es) 2008-12-19 2018-04-11 Vertex Pharmaceuticals Incorporated Derivados de pirazina útiles como inhibidores de la quinasa ATR
WO2010093561A1 (en) * 2009-02-11 2010-08-19 Liangping Yu Particulate composition and the method of making the same
US20120128667A1 (en) * 2009-05-01 2012-05-24 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013049859A1 (en) * 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
MX2017003463A (es) 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
CA2342981A1 (en) * 1998-09-25 2000-04-06 Warner-Lambert Company Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
WO2001034131A2 (en) * 1999-11-10 2001-05-17 Warner-Lambert Company Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339631B1 (no) * 2004-10-08 2017-01-16 Indena Spa Semisynteseprosess for fremstillingen av 10-deacetyl-N-debenzoyl-paklitaxel.

Also Published As

Publication number Publication date
CR8163A (es) 2006-07-14
CO5660262A2 (es) 2006-07-31
CA2634765A1 (en) 2004-12-02
NZ543591A (en) 2009-09-25
AU2004241873A1 (en) 2004-12-02
RS20050884A (sr) 2008-04-04
AU2004241873C1 (en) 2009-01-22
IL171941A0 (en) 2006-04-10
MXPA05012345A (es) 2006-02-08
TW200505424A (en) 2005-02-16
KR20060009371A (ko) 2006-01-31
CA2634709A1 (en) 2004-12-02
CA2527191A1 (en) 2004-12-02
CN1794991A (zh) 2006-06-28
ECSP056253A (es) 2006-10-25
AU2004241873B8 (en) 2008-05-29
CA2634766A1 (en) 2004-12-02
MEP32308A (en) 2010-10-10
ZA200509515B (en) 2006-07-26
RU2322971C2 (ru) 2008-04-27
CL2004001278A1 (es) 2005-05-06
RU2005140570A (ru) 2006-06-10
EP1626719A1 (en) 2006-02-22
BRPI0410959A (pt) 2006-07-04
UY28330A1 (es) 2004-12-31
UA81499C2 (en) 2008-01-10
CN101322707A (zh) 2008-12-17
JP2006526031A (ja) 2006-11-16
AU2004241873B2 (en) 2008-05-08
CU23490B7 (es) 2010-02-23
US20070098816A1 (en) 2007-05-03
KR100938712B1 (ko) 2010-01-25
PE20050206A1 (es) 2005-03-26
WO2004103369A1 (en) 2004-12-02
NO20055417D0 (no) 2005-11-16
AR045318A1 (es) 2005-10-26

Similar Documents

Publication Publication Date Title
NO20055417L (no) Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor
MXPA06000013A (es) Agente terapeutico para sarcoma de tejido suave.
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
EA202191361A1 (ru) Способы лечения муковисцидоза
NO20054681L (no) Farmasoytiske produkter
EP4208461A4 (en) NOVEL COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DK3976604T3 (da) 1,3,4-oxadiazol-derivatforbindelser som histondeacetylase 6-hæmmer og den farmaceutiske sammensætning, der omfatter den samme
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
ZA200708749B (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
HUE068516T2 (hu) 1,3,4-Oxadiazol-származék vegyületek mint hiszton-deacetiláz-6 inhibitorok és ilyen vegyületeket tartalmazó gyógyászati kompozíció
EP4110780A4 (en) 1,3,4OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONEDEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITION THEREOF
FR2867682B1 (fr) Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
DE602004020488D1 (de) Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
CA3247655A1 (en) HISTONE DEACETYLASE 6 (HDAC6) INHIBITION
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
AR052567A1 (es) Combinacion de bambuterol e inhibidor de integrina
AR055107A1 (es) Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)
NO20064337L (no) Farmasoytisk middel inneholdende hyaluronan som en aktiv ingrediens
MX2023007304A (es) Agente terapeutico para la fibrosis
CA3270009A1 (en) Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
HK40122695A (en) Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application